Physician

Juan Saucedo, D.O.

According to 2025 Medicare claims, Juan Saucedo, D.O. (NPI: 1104976539) practices family practice in the Eagle Pass, TX market, with the plurality of this provider's patient population coming from Maverick, TX. This provider's primary affiliated billing organization is SAUCEDO FAMILY CARE, PLLC (NPI: 1669912804; TIN: 814668904) and primary practice location at 78852-4118. Saucedo is affiliated with the WellMed Greater Texas Medicare ACO, LLC (ACO ID: A4895), participating under the MSSP model.

Saucedo's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 79 traditional Medicare patients, billed 1,602 HCPCS/CPT codes, and received $60,181 in Medicare payments. The top billing code was G0439 (Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit). Part D data shows 6,975 prescription claims across 335 beneficiaries totaling $2,005,367 in drug costs, led by Jardiance (Empagliflozin). 2023 DME data shows 11 claims. Open Payments data shows 44 records totaling $972. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $2,067 to $60,181. Similarly, Part D prescription costs have moved sharply higher in recent years, from $394,179 to $2,005,367. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $17,140 to $463.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	234	566	$2,067
2016	113	152	$8,863
2017	61	282	$20,749
2018	71	539	$38,368
2019	99	794	$46,608
2020	102	1,178	$61,441
2021	91	809	$54,914
2022	89	874	$50,783
2023	107	1,287	$58,131
2024	79	1,602	$60,181

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	855	6,710	$394,179
2016	439	1,837	$100,088
2017	170	913	$60,694
2018	149	1,662	$116,202
2019	252	3,399	$375,676
2020	307	5,172	$734,672
2021	273	5,245	$1,075,636
2022	319	5,609	$1,403,571
2023	323	6,699	$2,117,174
2024	335	6,975	$2,005,367

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	275	699	$17,669
2016	65	169	$1,397
2017	11	28	$246
2018	11	84	$2,242
2019	N/R	11	$189
2020	N/R	114	$7,953
2021	N/R	148	$5,808
2022	N/R	29	$611
2023	N/R	11	$282
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
G0439	Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit	32	32	$123
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	51	238	$123
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	50	161	$88
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	33	65	$12
96372	Injection of drug or substance under skin or into muscle	46	151	$10

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Jardiance	Empagliflozin	255	20,147	$405,786
Ozempic	Semaglutide	230	11,288	$361,990
Farxiga	Dapagliflozin Propanediol	212	15,806	$295,754
Mounjaro	Tirzepatide	145	5,970	$212,280
Rybelsus	Semaglutide	40	3,200	$103,158

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	44	$972	AstraZeneca Pharmaceuticals LP
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Juan Saucedo, D.O.?

Tedicare shows public-source Medicare data for Juan Saucedo, D.O. (NPI 1104976539), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Juan Saucedo, D.O. have ACO affiliation data?

Juan Saucedo, D.O. is shown with ACO affiliation data for WellMed Greater Texas Medicare ACO, LLC (MSSP, ACO ID A4895).

What billing organization is linked to Juan Saucedo, D.O.?

Juan Saucedo, D.O. is linked to SAUCEDO FAMILY CARE, PLLC (billing NPI 1669912804) in the available physician profile data.

Does Juan Saucedo, D.O. have Open Payments data?

Juan Saucedo, D.O. has 44 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.